Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression

NCT07183748 is registered in ClinicalTrials.gov with Beersheva Mental Health Center as lead sponsor.

NCT NCT07183748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07183748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Phase II Feasibility Study to Assess the Safety and Efficacy of Psilocybin Microdosing Combined With Psychotherapy in Treatment-resistant Depression
Lead sponsor
Beersheva Mental Health Center
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2025
Completion date
June 1, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

treatment resistant depression